榮昌生物-B(09995.HK)2022年度業績:產品銷售收益增長462%、研發開支增長38%
格隆匯3月29日丨榮昌生物-B(09995.HK)公佈,截至2022年12月31日止年度,實現收益7.68億元(人民幣,下同),同比下降46.08%;毛利4.98億元,同比下降63.31%;母公司擁有人應占虧損9.99億元,上年同期為純利2.76億元;基本每股虧損1.88元。
報吿期內,產品銷售收益約7.38億元,同比增長462.4%,主要得益於公司自身免疫類商業化產品泰它西普(RC18,商品名:泰愛®)及抗腫瘤類商業化產品維迪西妥單抗(RC48,商品名:愛地希®)進入國家醫保目錄後的銷售放量及銷售收入同比增長強勁。
值得注意的是,研發開支增加約2.71億元或約38.1%至2022年度約9.82億元。截至2022年12月31日止,銀行結餘及現金約20.69億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.